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ABSTRACT: Precise control of the oligomeric state of proteins is of central
importance for biological function and for the properties of biopharmaceutical
drugs. Here, the self-assembly of 2,2′-bipyridine conjugated monomeric insulin
analogues, induced through coordination to divalent metal ions, was studied.
This protein drug system was designed to form non-native homo-oligomers
through selective coordination of two divalent metal ions, Fe(II) and Zn(II),
respectively. The insulin type chosen for this study is a variant designed for a
reduced tendency toward native dimer formation at physiological concen-
trations. A small-angle X-ray scattering analysis of the bipyridine-modiﬁed
insulin system conﬁrmed an organization into a novel well-ordered structure
based on insulin trimers, as induced by the addition of Fe(II). In contrast,
unmodiﬁed monomeric insulin formed larger and more randomly structured assemblies upon addition of Fe(II). The addition of
Zn(II), on the other hand, led to the formation of small quantities of insulin hexamers for both the bipyridine-modiﬁed and the
unmodiﬁed monomeric insulin. Interestingly, the location of the bipyridine-modiﬁcation signiﬁcantly aﬀects the tendency to
hexamer formation as compared to the unmodiﬁed insulin. Our study shows how combining a structural study and chemical
design can be used to obtain molecular understanding and control of the self-assembly of a protein drug. This knowledge may
eventually be employed to develop an optimized in vivo drug release proﬁle.
■ INTRODUCTION
Protein-based drugs constitute a growing share of the
pharmaceutical market. Unfortunately, proteins are generally
more prone to degradation, as compared to most small-molecule
drugs.1 However, the properties of proteins can be modulated by
the addition of appendages, such as lipid chains and PEG.2 A
central research and development activity associated with protein
drug development concentrates on optimizing the protein drug
release proﬁle following injection. Discovering new approaches
to control the self-assembly of proteins, for example, to modulate
their function or to prolong their in vivo half-life, has extensive
research focus, both in academia and in the pharmaceutical
industry.3 The present study investigates diﬀerent strategies to
obtain better control of the nanoscale structural properties of
protein-based drugs using insulin as the model protein.
Insulin is a small protein of∼5.7 kDa. In its native form, it has a
preference for forming dimers through interactions between
hydrophobic surfaces. These dimers are the foundation for the
insulin hexamer that is built up from three dimers. In the
hexamer, the three dimers are held together by hydrophobic
surface contacts and by the coordination around two Zn(II)-
ions.4,5 Insulin is stored as hexamers in the pancreas and is
released into the bloodstream where its monomeric form is part
of the regulation of the glucose level in the blood.6 Diabetes, both
type 1 and 2, is associated with faults in the regulation of or
sensitivity to insulin levels. Current estimates are that 346million
people worldwide suﬀer from diabetes and that in 2004 3.4
million died due to eﬀects related to high blood sugar level. The
number of diabetic patients is expected to double during the next
20 years.7
In diabetes treatment, administration of insulin is often
required, and diﬀerent long-acting insulin drugs have been
developed to deliver the constant insulin level present in healthy
individuals and without which the diabetic patient is at risk of
hyperglycemia.8 In addition, several fast-acting insulin analogues
have been developed to establish the insulin peaks required
shortly after the intake of a meal.9,10 These fast-acting insulin
analogues generally have a tendency to resist oligomerization as
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compared to the long-acting analogues. In the present study, we
use one of these monomeric insulin types as a model protein. We
have selected the insulin analogue InsX2, which is produced at
NovoNordisk A/S for research purposes.10 Compared to human
insulin, InsX2 is modiﬁed at positions 9 and 27 on the B chain
where substitutions have beenmade to, respectively, Asp andGlu
(B9D, B27E; Chain, Position, Substituted with). Both
substitutions are made on the hydrophobic surface involved in
the formation of the insulin dimer. The alterations decrease the
propensity for dimerization and consequently also for hexamer
formation, resulting in a more monomeric insulin variant.10
It has previously been shown that 2,2′-bipyridine (bipy) linked
to GalNAc to form bipy-GalNAc can result in bipy-GalNAc
trimers by ligand binding between bipy and Fe(II),11 relying on
the strong propensity of Fe(II) for forming a tris complex with
the bidentate bipy ligand. Recently, we demonstrated that bipy
modiﬁed InsX2 variants would form ﬁrst published insulin trimer
upon the addition of Fe(II), as studied by chromatographic and
optical spectroscopic methods. The circular dichroism (CD)
data clearly proved formation of trimers, proving that the
geometry of the artiﬁcial metal ion site can drive protein
oligomerization, interestingly with orientations which depended
on the local chiral environment provided by B29 vs A1 positions
of InsX2.12 However, the study was limited, as the formation of
higher-order assemblies could not be studied by these methods.
Here, we report the structure and nanoscale properties of these
two InsX2-bipy variants upon the addition of Fe(II) or Zn(II)
ions, respectively, as studied by small angle X-ray scattering
(SAXS). The present SAXS analysis does conﬁrm that trimers are
formed from both InsX2-bipy variants upon addition of Fe(II).
However, we ﬁnd here that the monomer−trimer equilibrium
distribution is signiﬁcantly aﬀected by the bipy binding site and
that the InsX2-bipy[B29] system requires a higher excess of
Fe(II) to form trimers than the InsX2-bipy[A1]. We also ﬁnd
that these trimers do not appear when adding Zn(II) instead of
Fe(II). Instead, upon addition of Zn(II), the modiﬁed insulin
self-organizes into the native hexamer structure, however, to a
lesser extent than human insulin. Again, the equilibrium is
signiﬁcantly shifted toward monomers for the InsX2-bipy[B29]
system. Finally, we observe that the bipy binding site has a
signiﬁcant impact on the formation of larger molecular
assemblies. In both the original InsX2 and the InsX2-bipy[A1]
systems, addition of excess concentrations of Fe(II) and Zn(II),
respectively, leads to the formation of larger fractal-like molecular
assemblies based on monomers, trimers, or hexamers. However,
in the case of InsX2-bipy[B29] only trimers or hexamers are
observed depending on whether Fe(II) and Zn(II) is added. The
larger fractal-like assemblies of these are not observed. This
suggests that the functionalization with bipy at position [B29]
inhibits the formation of larger molecular assemblies and in this
way stabilizes the smaller and more well-ordered assemblies.
■ EXPERIMENTAL METHODS
Samples. Three insulin analogues were examined in this work:
InsX2, which is the unmodiﬁed monomeric insulin analogue, was kindly
provided by Novo Nordisk A/S; InsX2-bipy[B29], which is InsX2
modiﬁed with 2,2′-bipyridine at position B29; and InsX2-bipy[A1],
which is InsX2 modiﬁed with 2,2′-bipyridine attached at position A1.
InsX2-bipy[A1] and InsX2-bipy[B29] were synthesized as previously
described.12 The primary and tertiary structures of InsX2-bipy[B29] and
InsX2-bipy[A1] are illustrated in Figure 1. The systems were formulated
with and without Fe(II) or Zn(II) metal ions at diﬀerent molar ratios of
metal ion to InsX2.
For the SAXS measurements, InsX2, InsX2-bipy[A1], or InsX2-
bipy[B29] was dissolved in Milli-Q water, and the pH was lowered to
between pH 2 and pH 3 by addition of HCl. The protein concentration
of the stock solution was monitored with a Nanodrop 1000
spectrophotometer from Thermo Scientiﬁc.
Samples with No Added Metal Ions. InsX2, InsX2-bipy[B29],
and InsX2-bipy[A1] without Fe(II) or Zn(II) were used as reference
systems for the analysis of the systems formulated with metal ions. For
the preparation of the metal ion-free samples, the pH was raised, from
pH 2−3, to pH 7.5 and a concentrated HEPES buﬀer at pH 7.5 was
added to obtain a ﬁnal concentration of 10 mM Hepes. The samples
were adjusted with Milli-Q water, and the following ﬁnal concentrations
were obtained: InsX2, 2.4 mg/mL (422 μM); InsX2-bipy[B29], 3.0 mg/
mL (608 μM); and InsX2-bipy[A1], 2.7 mg/mL (542 μM).
Samples with Fe(II). To prepare the Fe(II)-containing samples,
diﬀerent amounts of Fe(Cl)2, dissolved in 0.1 M HCl, to prevent
oxidation, were added to vials of concentrated insulin solutions while
these were still at pH 2−3. The pH was then raised to pH 7.5, HEPES
buﬀer at pH 7.5 was added, and the volume was adjusted with Milli-Q
water to obtain a buﬀer concentration of 10 mM HEPES and the same
insulin concentrations as for the metal ion-free samples. The prepared
molar stoichiometries of Fe(II) to the various InsX2-analogues,
[Fe(II)]/[InsX2], are listed in Table 1. The solid Fe(Cl)2 was kept
dry and unoxidized through storage in a desiccator, and no sign of
Figure 1. Top: Primary structure of bipy and the InsX2 analogues. InsX2: R,R′ = H; InsX2-bipy[A1]: R = bipy, R′ = H; InsX2-bipy[B29]: R = H, R′ =
bipy. Bottom left: Tertiary structure of InsX2-bipy[A1]. Bottom right: Tertiary structure of InsX2-bipy[B29]. The tertiary structures are modiﬁed from
pdb structure 2JV1; not energetically optimized.
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oxidation of Fe(II) was observed in the solutions with the applied
procedures.
Samples with Zn(II). The samples with Zn(II) were prepared using
the same procedure as described for Fe(II) except that Zn(OAc)2 was
added at low pH instead of Fe(Cl)2. The pH was then raised to pH 7.5,
the Hepes buﬀer was added, and the volume was adjusted with Milli-Q
water to obtain a ﬁnal Hepes concentration of 10 mM. The prepared
molar stoichiometries of Zn(II) to the various InsX2-analogues,
[Zn(II)]/[InsX2], are listed in Table 1.
After the preparation, all samples were set to equilibrate for a
minimum of 8 h at 5 °C.
Small Angle X-ray Scattering Experiments. The SAXS measure-
ments were performed partly at the SAXS beamline I711 at MAX-lab,
Lund, Sweden,13 and partly at the ID14−3 beamline at ESRF, Grenoble,
France.14 Buﬀer backgrounds were measured before and after each
sample, and the averaged background was subtracted from the sample
measurement. For the data sets from I711, both the initial data reduction
including azimuthal averaging, q-calibration, absolute scattering
intensity calibration, and background subtraction were performed by
use of the BioXTAS RAW software.15 For the data sets from ID14−3, the
data reduction was performed by means of the fully automatized version
of the ATSAS package.16 As usual, the scattering data are represented as
a function of the momentum transfer q = 4π sin θ/λ, where λ is the X-ray
wavelength (1.1 Å at the I711 setup used and 0.931 Å at ID14−3) and θ
is the half scattering angle. By using the scattering from H2O and bovine
serum albumin, respectively, as external standards, the scattering
intensities, I(q), could be obtained in terms of the absolute scattering
cross sections per unit volume in units of cm2/cm3.
CD and Absorbance Spectrum Measurements. The CD
measurements were performed on a Jasco J-815 CD spectrometer
with a Jasco CDF-426 S/15 Peltier-element temperature controller,
attached to a Julabo water bath. Corresponding UV−vis absorbance
measurements were carried out on a Shimadzu UV2401PC instrument.
For the optical spectroscopy, the sample temperature was maintained at
25 °C, and Hellma quartz cuvettes of either 10 mm or 1 mm were used.
Blank spectra of reference solutions were recorded and subsequently
subtracted, and ﬁnally, the recorded data were converted to molar units.
■ THEORY AND MATHEMATICAL MODELING
The small-angle scattering intensity from a general sample of
particles in solution can be described by the product of a form
factor, P(q), describing the intraparticle scattering, a structure
factor, S(q), describing the interparticle interactions and a
prefactor, c, which may be calculated by the product of the
concentration of the particles, their molar mass and the second
power of their excess scattering length per unit mass17
= · ·I q c P q S q( ) ( ) ( ) (1)
The samples investigated in the present project consisted of a
mixture of diﬀerent oligomeric forms of InsX2-bipy. The overall
sample concentration was low and kept at ∼2.5 mg/mL,
implying that the structure factor, S(q), could be assumed to be
unity. Consequently, the following general expression for the
small-angle scattering could be used:
∑= ·I q c X P q( ) ( )
i
i i
(2)
where Xi denotes the weight fraction of the proteins that are in a
given oligomeric form, and Pi(q) describes the corresponding
form factor. In order to ensure mass-conservation, ∑iXi = 1.
Oligomeric particles, as those in focus in the present work, are
composed of small subunits, and the form factor P(q) may be
decomposed into the scattering from the single subunit, p(q),
and a function f(q) describing the eﬀect of the oligomeric
organization on the scattering:
= ·P q p q f q( ) ( ) ( ) (3)
The function f(q) may be a function describing the eﬀect of
organizing the monomeric subunit in a well-deﬁned oligomer
such as, e.g., a dimer or a hexamer. Alternatively, it may be a
function that describes a less-ordered structure, such as, e.g., the
structure of protein subunits aggregated into a fractal-like
structure.
Well-Ordered Oligomers. In the present work, it was
relevant to model the ordered structures of insulin monomers,
trimers, and hexamers, as well as fractal-like structures composed
of these subunits. Here, we here take advantage of the fact that
most of the ordered oligomeric subunits can be found in the
protein data bank, thus the f(q)’s corresponding to the ordered
oligomeric substructures were, in fact, not explicitly calculated.
Instead, P(q) values for the entire insulin monomer, trimer, or
hexamer were calculated using the program CRYSOL18
combined with information about the insulin crystal structure
from the protein data bank. For monomeric insulin, the PDB
structure 3I3Z.pdb was used.19 The hexamer structures were
generated from 1EV3.pdb by use of PYMOL.20 Putative 3D
structure models for the previously unknown quaternary trimer
structure for InsX2-bipy[B29] trimer and InsX2-bipy[A1] trimer
were generated in silico. To this end, the NMR solution structure
of the human insulin monomer21 (PDB ID: 2JV1) was obtained
from the protein data bank,22 and the ﬁrst structure of the
ensemble was extracted for further work. The B9D and B27E
mutations characteristic of InsX2 were introduced into the NMR
structure with the mutation functionality in Maestro.23
Subsequently, the bipyridine moiety was introduced at position
B29 or A1, yielding the InsX2-bipy[B29] monomer or InsX2-
bipy[A1] monomer, respectively. To generate the corresponding
trimers, the superposition function in Maestro was employed to
overlay the bipyridine moieties of three duplicates of the
bipyridine functionalized InsX2 monomer with the bipyridine
moieties in the crystal structure of a tris-(2,2′-bipyridine)
cobalt(III) complex.24 After substituting Fe(II) for Co(III), the
resulting trimer models were subjected to energyminimization in
MacroModel25 using the OPLS_200526 force ﬁeld and relaxed
convergence criteria (gradient <1.0 kJ Å−1 mol−1). This allowed
the removal of steric clashes while largely conserving the native
insulin geometry. Relevant PDB ﬁles were generated by means of
the software Visual Molecular Dynamics (VMD).27 In the process
of determining the trimer structure, diﬀerent geometry
optimization criteria were used and outputs were subsequently
converted to reciprocal space using CRYSOL and compared to
the experimental SAXS data. The structure that gave the best ﬁt
to the experimental data for the trimer was used for the
subsequent SAXS analysis. The applied form factor scattering
Table 1. Fe(II) and Zn(II) Series Measured on the InsX2
Analogues
sample [Fe(II)]/[InsX2]
InsX2 0 0.13 0.25 0.51 0.75
InsX2-bipy[B29] 0 0.1 0.2 0.3 0.7
InsX2-bipy[A1] 0 0.1 0.3 0.7
sample [Zn(II)]/[InsX2]
InsX2 0 0.2 0.3 0.6 0.09
InsX2-bipy[B29] 0 0.1 0.3 0.7
InsX2-bipy[A1] 0 0.1 0.3 0.7
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intensities for the insulin monomer, trimer, and hexamer are
plotted in Figure S1 of Supporting Information.
Fractal-Like Oligomers. In the case of the larger oligomeric
structures also observed in this project, the fractal model
developed by Teixeira28 was used. The model (eq 4) describes
the scattering of aggregates from a subunit characterized by an
interaction radius r0, fractal dimension D, and correlation length
ξ:
ξ
ξ
= +
·
·Γ −
+ ·
· − · ·
−
−
⎡⎣ ⎤⎦
⎡⎣ ⎤⎦
f q
q r
D D
q
D q
( ) 1
1
( )
( 1)
1 1/( )
sin ( 1) tan ( )
D Dfrac
0 2 2
( 1)/2
1
(4)
In eq 4, Γ(x) denotes the gamma function. In the present work,
the fractal model is combined with a numerical form factor for an
insulin monomer, hexamer, or trimer using a previously
developed strategy.29,30 By combining the form factor of the
insulin subunit with the fractal model through the so-called
decoupling approximation,31 it is taken into account that the
insulin subunit is not centrosymmetric. The fractal model in
combination with the form factor for subunit i is denoted Ffrac[q,
Pi(q)]. The value for r0 was determined from the halfDmax values
based on the PDB structures and was ﬁxed to r0 monomer = 19 Å,
r0 trimer = 24 Å, and r0 hexamer = 24 Å. Examples of the fractal-like
structured assemblies of the insulin monomer, trimer and
hexamer are plotted in ﬁgure S1 of Supporting Information.
Mixtures of Diﬀerent Oligomers.A scenario where there is
equilibrium between diﬀerent oligomeric states is readily
described by combination of eqs 2 and 3:
∑= · ·I q c X p q f q( ) ( ) ( )
i
i i i
(5)
In the case of a sample composed of a mixture of, e.g., monomers,
trimers, and fractals composed from monomers eq 5 becomes
= + +I q c X P q X P q X F
q P q
( ) { ( ) ( )
[ , ( )]}
mon mon tri tri SAmon frac
mon (6)
where fmon(q) = 1 such that pmon(q) = Pmon(q). Further details
about the speciﬁc models used in the diﬀerent experimental cases
are provided in the Results section along with the obtained
model ﬁt parameters.
Analysis Software. All models were implemented in an in-
house made Fortran77 program containing a least squares ﬁtting
(LSF) routine that allowed ﬁtting the mathematical models to
the experimental data. As described above, CRYSOL was used to
determine the numerical scattering intensities corresponding to
the well-ordered oligomeric states, and as described in more
detail elsewhere,29 the information about the form factor
amplitudes was also obtained from the CRYSOL output ﬁles.
■ RESULTS
In the following, the results of the SAXS analysis of the three
diﬀerent insulin analogues prepared with, respectively, Fe(II) or
Zn(II) are presented. The data are rescaled in all plots to allow
for evaluation of the quality of the model ﬁts. An unscaled data
representation of the data is plotted in Figure S2 of the
Supporting Information.
Structural Rearrangements Introduced by Titration of
Insulin Analogues with Fe(II). InsX2 with Fe(II). In this
experiment, samples of unmodiﬁed InsX2 were prepared with
increasing amounts of Fe(II) as described in Experimental
Methods. SAXS data were obtained at the SAXS beamline I711 at
MAX-lab, Sweden. The aim of the series was to investigate the
behavior of InsX2 in the presence of Fe(II) as a reference for the
InsX2-bipy measurements. The obtained SAXS data are plotted
in Figure 2a. It is readily seen that the intensity in the low q part of
the data increases with increasing Fe(II) concentration. This
clearly indicates that, although InsX2 has no bipy moiety that can
bind Fe(II), the addition of Fe(II) still leads to the formation of
larger but less ordered molecular assemblies.
To obtain a better and more quantitative description of the
formed structures, the SAXS data were simulated using the
following special case of eq 5 and keeping 1 = Xmon + XSA,mon:
= · +I q c X P q X F q P q( ) { ( ) [ , ( )]}mon mon SA,mon frac mon (7)
This analysis showed that the pure InsX2 data were consistent
with a model for monomeric insulin, thus having Xmon = 1 and
XSA,mon = 0. Titration of more and more Fe(II) into the sample
gave rise to structures that could best be described as long,
slightly branched insulin aggregates built from monomers. A
decreasing fraction of monomers, Xmon, and a correspondingly
increasing fraction, XSA,mon, of these fractal-like aggregates were
observed. Furthermore, an increase of both the fractal dimension,
D, and the correlation length, ξ, was observed. The growth of the
Figure 2. (a) SAXS data (colored points) and model ﬁts (full black lines). The InsX2 data (yellow points) are on absolute scale. The above data are
rescaled by 3n, where n runs from 1 to 4. (b) (I) monomeric insulins. (II) Insulin assemblies built from monomeric insulin subunits with a fractal
dimension close to 1. (III) Branched insulin assemblies built from monomeric insulin subunits.
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fractal dimension corresponds to the transition from a needle-
like to a more branched structure.32 Had the correlation length
been relatively constant and independent of the Fe(II)
concentration, that would have indicated an ordered repetitive
substructure in the molecular assemblies. The observation of an
increasing correlation length, however, suggests that the
molecular assemblies do not possess such a repetitive
substructure and they are not well-ordered. In the process of
analyzing the data, a more simple model that assumed all the
insulin took part in the molecular assemblies, i.e., a model that
assumed XSA,mon = 1, was evaluated for the samples with Fe(II)
concentrations above zero. However, this model failed to
describe the experimental data at the three intermediate Fe(II)
concentrations. The simulation results are summarized in Table
2. The corresponding model ﬁts are shown in Figure 2a and the
formed structures are illustrated Figure 2b.
InsX2-bipy[B29] with Fe(II). The goal of modifying insulin X2
with bipy[B29] was, vide supra, to develop a protein which
formed trimers upon addition of Fe(II). Thus, a Fe(II) titration
scan of InsX2-bipy[B29] was performed and studied by SAXS at
the ID14−3 beamline at ESRF, France. The obtained data are
shown in Figure 3a. A sharp upturn in the intensity at low q-
values is observed in all data sets. The upturn shows that
aggregates were present in the sample even before Fe(II) was
added. However, we observe that aggregation does not increase
with titration of Fe(II) suggesting that the aggregated part was
already present in the stock solution and is unaﬀected by the
Fe(II) addition. The data analysis shows that the SAXS data from
InsX2-bipy[B29] in the presence of varying concentrations of
Fe(II) can be described very well as a combination of insulin
monomers, insulin trimers, and a constant fraction of
preaggregated insulin. While the titration of Fe(II) leads to a
gradual decrease of the monomer fraction and a corresponding
increase of the trimer fraction, the preaggregated insulin fraction
remained constant. Thus, the experimental data could be ﬁtted
directly by eq 6. The presence of the preaggregated insulin is
unfortunate and could most likely have been dealt with by careful
centrifugation prior to the experiments. However, the volume
fraction of the preaggregated insulin is only minor and its eﬀect is
negligible on the high-q part of the data, which contains the
information about the monomer to trimer transition.
In order to determine the structure of the trimers, we exploited
our previous ﬁndings12 that indicated that the InsX2-bipy[B29]
trimers formed with Fe(II) are primarily of facial ( fac)
stereochemistry. Several hypothetical PDB structures for the
InsX2-bipy[B29] trimer were generated for both the meridional
(mer) and fac isomers of the trimer and tested against the SAXS
data. The model ﬁtting to the very high-quality SAXS data clearly
conﬁrmed that the fac isomeric geometry was the dominating
species.
In order to describe the fractal-like aggregates visible in the
scattering data as the sharp upturn at low q, it was found that the
fractal dimension, D, had to be ﬁxed to a value of 3,
corresponding to a rather compact aggregate. For the volume
fraction of the large insulin aggregates, XSA,mon, and the
correlation length of the aggregates, ξ, the solution space was
much larger, and many pairs of the two variables gave good
Table 2. InsX2 Formulated with Fe(II)Model Fit Resultsa
[Fe(II)]/[InsX2] Xmon
c [%] XSA,mon [%] ξ [Å] D
0 100 0 n.a. n.a.
0.13 57.4 42.6 ± 0.9 58 ± 6 1.13 ± 0.04
0.25 63.8 36.2 ± 1.7 110 ± 12 1.50 ± 0.04
0.51 12.0 88.0 ± 0.3 261 ± 17 1.50 ± 0.07
0.75 0 100b 280 ± 18 1.57 ± 0.01
aXmon: The fraction of InsX2 that is in monomeric form. XSA,mon: The
fraction of InsX2 that participates in larger assemblies. ξ is the
correlation length and D the fractal dimension of the larger monomer-
based assemblies. bParameter ﬁxed manually. cXmon is calculated using
Xmon = 1 − XSA,mon.
Figure 3. (a) SAXS data (colored points) and model ﬁts (full black lines). The InsX2-bipy[B29] data (yellow points) are on absolute scale. The above
data have been rescaled by 3n where n runs from 1 to 4. (b) (I) Free monomeric insulin. (II) Assemblies built from monomeric insulin. (III) Insulin
trimer coordinating around a Fe(II) ion.
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solutions. The values XSA,mon = 1% and a ξ = 4200 Å were used.
This gave a good description of the upturn in all cases and
allowed for focusing on the Fe(II) induced transition from
monomeric to trimeric insulin visible at high q.
The resulting model ﬁts are plotted in Figure 3a, the ﬁt
parameters are reported in Table 3, and the corresponding
structures are illustrated in Figure 3b. It is clear from the
modeling outputs that the amount of trimers formed increased
with the Fe(II) concentration from 0% to a maximum close to
100%.
InsX2-bipy[A1] with Fe(II). InsX2-bipy[A1] was the third
insulin analogue investigated; it had also been designed to form
trimers upon addition of Fe(II). SAXS data were obtained at
beamline I711 at MAX-lab, Sweden. As for InsX2-bipy[B29], the
aim of the InsX2-bipy[A1] series was to investigate the InsX2-
bipy[A1] trimer formation upon addition of Fe(II). The
obtained data are plotted in Figure 4a.
When inspecting the data set for InsX2-bipy[A1] in Figure 4a,
it can be seen from the lack of a Guinier region at low q that there
is already a high degree of molecular assembly present in the
sample even before Fe(II) is added to the sample. However, the
titration with Fe(II) clearly leads to further growth of the size of
the molecular assemblies in the sample as observed from the
increase in the low-q scattering with increasing Fe(II)
concentration. The data from this series were modeled with a
further generalized version of eq 6 that included the possibility of
having fractal-like aggregates from both monomeric and trimeric
subunits:
= · + · + ·
+ ·
I q c X P q X P q X
F q P q X F q P q
( ) { ( ) ( )
[ , ( )] [ , ( )]}
S ,mon mon tri tri A mon
frac mon SA,tri frac tri (8)
where, analogous to the more simple cases, Xmon +Xtri + XSA,mon +
XSA,tri = 1. In practice, none of the data sets contained enough
information to allow for ﬁtting all four terms of eq 8 at the same
time. The results reported in the following are hence the best
compromise in the need to minimize the number of ﬁtting
parameters while still obtaining good model ﬁts.
The InsX2-bipy[A1] sample without Fe(II) was modeled as a
combination of monomers and assemblies of monomers, i.e., by
having Xtri = XSA,tri = 0 in eq 8 such that it reduces to eq 7. This
suggested that 72% of the sample was still in monomeric form,
while the remaining 28% of the insulin formed larger assemblies
that could be described as slightly branched structures, with a
fractal dimensionD of 1.4. A correlation length, ξ, of∼200 Å was
found. Since this type of structure is not observed for InsX2, it is
clear that the molecular assemblies must be mediated by bipy, as
expected. If the molecular assemblies were due to simple pairs of
bipy−bipy interactions, the size of the assemblies would be
expected to be limited by geometry, as the InsX2 is much larger
than the bipy moiety. This is not the case, which suggests an
interaction between the bipy group of one molecule and the
InsX2 of another molecule, e.g., hydrophobic, ionic, and so forth.
This would allow the formation of chains and branched chains, in
accordance with the modeling results.
Table 3. InsX2-bipy[B29] Formulated with Fe(II)Model
Fit Resultsa
[Fe(II)]/[InsX2-bipy[B29]] Xmon [%]
c Xtri [%] XSA,mon [%]
0 99 0b 1b
0.1 88.7 10.3 ± 0.2 1b
0.2 77.2 21.8 ± 0.2 1b
0.3 61.1 37.9 ± 0.3 1b
0.7 0 99b 1b
aXmon: The fraction of insulin that is in monomeric form. Xtri: The
fraction of insulin that is in trimeric form. XSA,mon: The fraction of
insulin that participates in larger assemblies. bParameter ﬁxed
manually. cXmon is calculated using Xmon = 1 − (Xtri + XSA,mon).
Figure 4. (a) SAXS data (colored points) andmodel ﬁts (black lines). The InsX2-bipy[A1] data (light blue points) are on absolute scale. The above data
are rescaled by 3n where n runs from 1 to 3. (b) (I) Monomeric insulin. (II) Assemblies built from monomeric insulin subunits. (III) Trimer built from
monomeric insulin around a Fe(II) ion. (IV) Assemblies built from trimer insulin subunits.
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Our recent CD data revealed an opposite handedness of the
bipy-Fe(II) complexes.12 Here, the fac isomeric trimer structure
found for InsX2-bipy[B29] was tested as input for the modeling
of the InsX2-bipy[A1] samples with Fe(II) and turned out to be
in good agreement with the experimental data.
During the modeling of InsX2-bipy[A1] with Fe(II), it was
found that, depending on the concentration of Fe(II), the system
could be described as either (1) a mixture of monomeric insulin,
trimeric insulin, and assemblies of monomer insulin, which was
observed at low Fe(II) concentrations, or (2) a combination of
monomeric insulin, trimeric insulin, and assemblies of trimers as
was observed at high Fe(II) concentrations. While it is most
likely that some of the samples contain all four species in eq 8, the
experimental SAXS data do not allow for such a detailed
decomposition.
For the samples with high concentrations of Fe(II), the data
suggest that, since almost all the bipy in the sample coordinated
to Fe(II) and formed trimers, the aggregation of trimers was due
to Ins−Ins binding mediated by the Fe(II).
The obtained model ﬁts are plotted in Figure 4a, the
corresponding ﬁt parameters are listed in Table 4, and the
obtained structures are illustrated in Figure 4b.
Structural Rearrangements Introduced by Titration of
Insulin Analogues with Zn(II). InsX2 with Zn(II). The SAXS
data from InsX2 titrated with Zn(II) were obtained at the I711
beamline at Max-Lab, Sweden. As discussed above, the InsX2
without metal ions is primarily in monomeric form. As Zn(II)
was titrated into the InsX2 sample, an increase of the scattering at
low q was observed (Figure 5a) and a kink of the I(q) at
approximately q = 0.03 Å−1 appeared. The analysis showed that
the data could be described as a mixture of monomers, hexamers,
and assemblies of hexamers, according to eq 9:
= · + · +
·
I q c X P q X P q X
F q P q
( ) { ( ) ( )
[ , ( )]}
,mon mon hex hex SA hex
frac hex (9)
When inspecting the obtained values for Xmon, Xhex, and XSA,hex
in Table 5, it is seen that, with increasing Zn(II) concentration,
Table 4. InsX2-bipy[A1] Formulated with Fe(II)Model Fit Resultsa
[Fe(II)]/[InsX2-bipy[A1]] Xmon
c [%] Xtri [%] XSA,mon [%] XSA,tri [%] ξmon [Å] Dmon ξtri [Å] Dtri
0 72.3 0b 27.7 ± 2.1 n.a. 198 ± 56 1.39 ± 0.07 n.a. n.a.
0.1 40.8 43.1 ± 1.1 16.1 ± 0.5 0b 198b 1.39b n.a. n.a.
0.3 25.74 72.1 ± 1.1 0b 2.16 ± 0.04 n.a. n.a. 309b 1.43b
0.7 0b 52.8d 0b 47.2 ± 0.7 n.a. n.a. 309 ± 25 1.43 ± 0.01
aXmon: The fraction of insulin that is in monomeric form. Xtri: The fraction of insulin that is in trimeric form. XSA,mon: The fraction of monomeric
insulin that participates in larger assemblies. XSAtri: The fraction of trimeric insulin that participates in larger assemblies. ξmon is the correlation length
and Dmon the fractal dimension of the monomer assemblies. ξtri is the correlation length and Dtri the fractal dimension of the trimer assemblies.
bParameter ﬁxed manually. cXmon is calculated using Xmon = 1 − (Xtri + XSA,mon + XSA,tri). dCase where Xtri is calculated using Xtri = 1 − XSA,tri.
Figure 5. (a) SAXS data (colored points) and model ﬁts (full black lines). The InsX2 data (yellow points) are on absolute scale. The above data are
rescaled by 3n where n runs from 1 to 4. (b) (I) Monomeric insulin. (II) Cartoon of hexameric insulin. (III) Assemblies built from hexameric insulin
subunits.
Table 5. InsX2 Formulated with Zn(II)Model Fit Resultsa
[Zn(II)]/[InsX2] Xmon [%] Xhex [%] XSA,hex [%] ξ [Å] D
0 100c 0b n.a. n.a. n.a.
0.2 91.3c 8.7 ± 0.3 0b n.a. n.a.
0.3 78.2 ± 0.7 19.1d 2.7 ± 0.1 100 ± 13 2.04 ± 0.06
0.6 58 ± 1 36d 6.2 ± 0.1 140 ± 15 1.84 ± 0.05
0.9 53 ± 2 35d 11.8 ± 0.3 142 ± 17 1.80 ± 0.04
aXmon: The fraction of insulin that is in monomeric form. Xhex: The fraction of insulin that is in hexameric form. XSA,hex: The fraction of insulin that
participates in larger assemblies with hexameric subunits. ξ is the correlation length of the assemblies and D is their fractal dimension. bParameter
ﬁxed manually. cXmon is calculated using Xmon = 1 − (Xhex + XSA,hex). dXhex is calculated using Xhex = 1 − (Xmon + XSA,hex).
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the hexamers started to form larger assemblies before all the
InsX2 had formed hexamers. This suggests that Zn(II), besides
inducing hexamer formation, can also to a lesser extent mediate
an attraction between already formed hexamers. Whether this is
due to the existence of a speciﬁc ligand binding site at the water-
exposed side of the insulin remains to be investigated. It can be
noted, however, that, in a Zn4 T3R3 insulin hexamer crystal
structure, there is evidence for the presence of a Zn-binding site
at the hexamer surface, with Zn coordination by HisB5 from
diﬀerent hexamers.33 Here, we ﬁnd that addition of Zn(II) to
InsX2 leads to the formation of both InsX2 hexamers and to
branched assemblies of InsX2 hexamers, with a fractal dimension
D of ∼1.8 and a correlation length ξ of ∼140 Å.
For the two samples with the highest amounts of Zn(II), we
were unable to obtain fully satisfactory ﬁts in the q-region from
∼0.02 Å−1 to ∼0.05 Å−1. A marked kink is observed in the
experimental data at ∼0.03 Å−1 as an indication of a well-deﬁned
characteristic length, but the kink is not reproduced by the
model. This indicates that the description provided by eq 9 of a
mixture of separated monomers, hexamers, and fractal-like
assemblies of hexamers is a slightly too simplistic picture of the
sample; and most likely, mixed aggregates will be present, e.g.,
fractal-like aggregates of monomers, dimers, and hexamers. An
attempt to ﬁt the data and in particular the observed kink with a
model approach previously developed to describe casein micelles
was also tried.34 In this approach, the particles are described as
larger, e.g., spherically shaped aggregates with a protein or other
appropriate substructure depending on the actual sample. While
this approach gave a decent description of the kink-region, it
failed to give good model ﬁts to the remaining part of the data,
and the approach was not applied further.
The obtained model ﬁts using eq 9 are plotted in Figure 5a, the
corresponding ﬁt parameters are listed in Table 5 and a cartoon
of the systems is provided in Figure 5b.
CD Analysis of Ins-bipy Titrated with Zn(II). The trimer
formation in the InsX2-bipy[A1] and InsX2[B29] with Fe(II)
systems was previously studied by CD spectroscopy.12 In order
to complement the SAXS analysis of the InsX2-bipy in the
presence of Zn(II), CD and near-UV absorption measurements
were performed on the InsX2-bipy[A1] under similar conditions
to investigate if insulin trimers formed when adding Zn(II). For
the InsX2-bipy[A1], optical spectroscopy in the near-UV spectra
showed absorption from the π−π* transition of the bipy
chromophore overlapping the weaker signal from the Tyr side-
chains of the insulin. Thus, the absorption spectrum in the
absence of Zn(II) displayed a ∼280 nm peak, and in the
corresponding CD spectrum, a weak positive signal was observed
in the same region. Gradual addition of Zn(II) red-shifts the
absorbance, and a new peak was observed with maxima at 305
and 318 nm and with isosbestic points at 275 and 300 nm in
agreement with metal ion coordination by bipy. The CD
spectrum similarly displayed a red-shifted signal with two local
maxima above 300 nm. The observed positive CD signal above
300 nm is likely to correspond to a single bipy unit from InsX2-
bipy[A1] binding Zn(II) under the inﬂuence of the chiral
environment of the protein. It is important to note that the
observed bipy CD signals in Figure 6 do not correspond to the
characteristic exciton signature of a tris bipy coordination
environment, thus suggesting that trimers are not formed. It
must be said, however, that, in theory, equal amounts ofΔ andΛ
optical isomer trimers might have been formed such that the CD
signals would cancel each other out.
InsX2-bipy[B29] with Zn(II). SAXS measurements of the
InsX2-bipy[B29] samples titrated with increasing concentrations
of Zn(II) were performed at the ID14−3 beamline at ESRF,
France. As explained above, the CD analysis did not indicate the
formation of bipy-induced trimers upon addition of Zn(II) in the
InsX2-bipy[A1]-system, and trimers were therefore also not
expected in the InsX2-bipy[B29]-system. This expectation was
conﬁrmed in the SAXS data analysis where we found the best
agreement between experimental data and model ﬁts by using a
combination of monomers, hexamers, and monomer-based
fractal-like aggregates:
= · + · +
·
I q c X P q X P q X
F q P q
( ) { ( ) ( )
[ , ( )]}
mon mon hex hex SA,mon
frac mon (10)
An upturn at low q similar to the one observed in the
preparations of InsX2-bipy[B29] with Fe(II) is present in the
data. The two sets of samples were prepared from the same stock,
and as in the preparation with Fe(II), no signiﬁcant dependence
was observed between the upturn and the amount of titrated
metal ion. The upturn could be suﬃciently well accounted for by
the same approach and model parameters as in the analysis of the
InsX2-bipy[B29] with Fe(II). This allowed for focusing on the
information present in the intermediate to high q data. As can be
seen in Figure 7a, the high q part of the SAXS data only changes
slightly upon the addition of Zn(II), thus indicating only minor
structural changes. This observation is supported by the model ﬁt
parameters reported in Table 6, which show that the sample only
reacts weakly upon the addition of Zn(II) as compared to the
above-described ordinary InsX2 sample with Zn(II). Our
analysis suggests that when [InsX2-bipy[B29]]/[Zn(II)] = 0.7
Figure 6. Near-UV absorption (upper panel) and CD (lower panel) of
181 μM InsX2-bipy[A1]. The following [Zn(II)]/[InsX2] stoichiome-
tries were employed: 0, 0.29, 0.45, and 0.62.
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is ﬁtted with model described by eq 10 then only 21% of the
InsX2-bipy[B29] are in hexamer form, while there are no
indications of the more unspeciﬁc Zn(II)-mediated Ins−Ins
interactions that gave rise to the large fractal-like structures
observed in the pure InsX2 system. Thus, InsX2-bipy[B29] seem
to have both a lower tendency to form hexamers and a lower
tendency to form hexamer-based larger aggregates, and the
monomeric insulin is by a large margin the dominating species.
A weak depression around q = 0.02 Å−1 followed by a slightly
higher scattering intensity around q = 0.05 Å−1 is also observed.
For protein samples, which have a nearly homogeneous
scattering length density, the most obvious explanation to this
eﬀect is a weak repulsive interaction between the single proteins.
Indeed, using a previously developed strategy29 for the
incorporation of a hard-spheres structure factor in the modeling
of the free monomer and hexamer insulins allowed for a superior
model ﬁt to the scattering data at intermediate q-values (results
not shown). However, as the structure factor eﬀect is weak and
mainly aﬀects data in the intermediate q-range, while the
information about the monomer to hexamer transition is mainly
present at high q-values, the two types of information do to a
good approximation not interfere. Hence, in practice the same
results for the monomer to hexamer fractions were obtained with
and without the structure factor incorporated. For simplicity, we
have therefore chosen only to report the ﬁt results obtained
without structure factor, i.e., eq 10. The obtained model ﬁts are
plotted in Figure 7b, a cartoon of the structures is provided in
Figure 7b, and the model ﬁt parameters are reported in Table 6.
InsX2-bipy[A1] with Zn(II). SAXS data from InsX2-
bipy[A1] with Zn(II) were obtained at the I711 beamline at
Max-lab, Sweden. The obtained data were best described as a
combination of monomers and hexamers in combination with
fractal-like aggregates of, respectively, monomers and hexamers:
= · + · + ·
+ ·
I q c X P q X P q X
F q P q X F q P q
( ) { ( ) ( )
[ , ( )] [ , ( )]}
mon mon hex hex SA,mon
frac mon SA,hex frac hex (11)
where, as usual, Xmon + Xhex + XSA,mon + XSA,hex = 1. As in the case
of InsX2-bipy[A1] with Fe(II), not all the terms of the model
were ﬁtted in any of the data sets. As explained above, the InsX2-
bipy[A1] with no added metal ions consists of monomers and
chain-like assemblies of monomers. As more and more Zn(II)
was added to the system, a population of hexamers ﬁrst appeared,
and then a population of aggregated hexamers appeared at the
highest Zn(II) concentration. As in the InsX2-bipy[A1] with
Fe(II) system, it is most likely that the samples will contain
populations of monomer-based and hexamer-based aggregates,
as well as even mixed monomer−hexamer aggregates. However,
the information contained in our experimental data did not allow
for introducing these more advanced descriptions while at the
same time obtaining reliable estimates of the ﬁt parameters, and
the model was restrained to the more simple approximation
provided above. The model-ﬁts are shown in Figure 8a, the
corresponding structures are illustrated in Figure 8b, and the
obtained ﬁt parameters are reported in Table 7.
Figure 7. (a) SAXS data (colored points) andmodel ﬁts (full black lines). InsX2-bipy[B29] data (light blue points) are on absolute scale. The above data
are rescaled by 3n where n runs from 1 to 3. (b) (I) Monomeric insulin. (II) Assemblies of monomeric insulin. (III) Insulin hexamers.
Table 6. InsX2-bipy[B29] with Zn(II)Model Fit Resultsa
[Zn(II)]/[InsX2-bipy[B29]] Xmon
c [%] Xhex [%] XSA,mon [%]
0 99 0b 1b
0.1 99 0b 1b
0.3 95.3 3.7 ± 0.8 1b
0.7 77.6 21.4 ± 0.2 1b
aXmon: The fraction of insulin that is in monomeric form. Xhex: The
fraction of insulin that is in hexameric form. XSA,mon: The fraction of
insulin that participates in larger assemblies with monomeric subunits.
bParameter ﬁxed manually. cXmon is calculated using Xmon = 1 − (Xhex
+ XSA,mon).
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■ DISCUSSION
Our recently reported chromatographic and optically based
study demonstrated that both bipy-functionalized InsX2 variants
form trimers in the presence of Fe(II).12 However, the CD data
did not provide information on the higher-order self-assembly of
the InsX2-bipy variants. The present SAXS-based structural
study indeed not only conﬁrmed the presence of these trimers,
but also suggests that there were other interaction sites for
divalent metal ions in this insulin-based system, which gave rise
to the formation of larger and less ordered structured assemblies
with the trimers or the hexamers as the basic “building blocks”.
Binding sites for metal ions, e.g., Co3+ and Ca2+ in insulin have
previously been found inside the insulin hexamer35,36 and have
been shown to stabilize this. The present study and the
observation of large metal ion-mediated assemblies, however,
indicate that some type of interaction sites are present at the
water-exposed part of the X2 insulin surface, including on the X2
insulin hexamer.33 The SAXS analysis furthermore showed that
both location of the bipy and the type of metal ion, Fe(II) or
Zn(II), signiﬁcantly aﬀected the self-assembly behavior and thus
the nanoscale structures of the formed molecular assemblies. An
overview of the rich structural behavior of the system as
determined from the SAXS analysis is provided in Figure 9.
In summary, we ﬁnd that insulin trimers form when adding
Fe(II) to both the InsX2-bipy[A1] and the InsX2-bipy[B29]
system. When Fe(II) is added to insulin at a molar ratio of 0.7,
both systems are saturated and are composed of ∼100% insulin
trimers. However, the analysis clearly shows that, in the InsX2-
bipy[A1] system, the trimers form and become predominant at
much lower Fe(II) concentrations than in the InsX2-bipy[B29]
system.
The analysis previously performed byMunch et al.12 suggested
that the trimers formed in the InsX2-bipy systems were most
likely fac isomeric. In the present SAXS analysis on the same
system, both the fac and mer conformations were tested as
structural inputs for the modeling routines. The mer con-
formations were unable to ﬁt the high q part of the SAXS data,
whereas the fac conformation ﬁtted the data sets very well, clearly
showing that the insulin trimers formed had a preference for the
fac. Munch et al.12 showed that InsX2-bipy[B29] and InsX2-
bipy[A1] have opposite enantiomeric excess (Δ/Λ). The
resolution of the SAXS data does, however, not allow for a
distinction between the two enantiomers, and the same structure
was used for both the InsX2-bipy[B29] and InsX2-bipy[A1]
trimers.
The CD analysis of the InsX2-bipy[A1] system with Zn(II)
strongly indicated that Zn(II) does not promote trimer
formation in these systems, as no exciton signal was observed.
However, there was clear evidence from CD and absorbance that
some Zn(II) ions coordinate to single bipy units. The SAXS
analysis of the same systems showed that part of the Zn(II) ions
give rise to the formation of insulin hexamers, even though the
Figure 8. (a) SAXS data (colored points) and model ﬁts (full black lines). InsX2-bipy[A1] data (light blue points) are on absolute scale. The above data
are rescaled for readability by 4n where n runs from 1 to 3. (b) (I) monomeric insulin. (II) Assemblies of monomeric insulin. (III) Insulin hexamer. (IV)
Assemblies built from hexameric insulin.
Table 7. InsX2-bipy[A1] Formulated with Zn(II)Model Fit Resultsa
[Zn(II)]/[InsX2-bipy[A1]] Xmon [%] Xhex [%] XSA,mon [%] XSA,hex [%] ξmon [Å] Dmon ξhex [Å] Dhex
0 72.3c 0b 27.7 ± 2.1 n.a. 198 ± 56 1.39 ± 0.07 n.a. n.a.
0.1 62.0c 5.2 ± 0.1 32.8 ± 0.5 0b 198b 1.39b n.a. n.a.
0.3 54.7c 27.0 ± 0.7 18.3 ± 0.1 0b 198b 1.39b n.a. n.a.
0.7 54.5b 21.8d 0b 23.7 ± 0.8 n.a. n.a. 180 ± 18 1.37 ± 0.03
aXmon: The fraction of insulin that is in monomeric form. Xhex: The fraction of insulin that is in hexameric form. XSA,mon and XSA,hex: The fraction of
insulin that participates in larger assemblies with, respectively, monomeric and hexameric subunits. ξ is the correlation length of the assemblies in
question and D is their fractal dimension. bParameter ﬁxed manually. cXmon is calculated using Xmon = 1 − (Xhex + XSA,mon + XSA,hex).
dXhex is
calculated using Xhex = 1 − (Xmon + XSA,mon + XSA,hex).
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monomer−hexamer equilibrium is signiﬁcantly shifted toward
monomers as compared to native human insulin. It is noteworthy
that the Zn(II) concentration dependence of the hexamer
formation and the formation of larger hexamer assemblies were
comparable in the InsX2 and the InsX2-bipy[A1] systems, while
the propensity of the Zn(II) induced hexamer formation was
signiﬁcantly lower in the InsX2-bipy[B29]-system. Hence, we
observe that the bipy modiﬁcation of the insulin in position B29
impairs the formation of both Fe(II) induced trimers and Zn(II)
induced hexamers.
It is also very interesting to note that the large fractal-like
molecular assemblies were much more abundant in the InsX2
and InsX2-bipy[A1] systems than in the InsX2-bipy[B29]
system. Thus, the bipy modiﬁcation in position B29 not only
impairs the speciﬁc oligomer formation, but also the unspeciﬁc
higher oligomer formation, whether this has monomers, trimers,
or hexamers as the basic building blocks.
The pharmaceutical implication of this ﬁnding is apparent.
InsX2 has been designed as monomeric insulin with limited
propensity for dimerization. If insulin drugs are injected
subcutaneously, larger oligomers yield slower diﬀusion into the
bloodstream leading to protracted drug delivery. Adding a
synthetic side-chain to the B29 site can potentially impair the
hexamer formation of InsX2 and consequently prevent assembly
of larger hexamer-based aggregates. Another important aspect is
that the receptor binding is not impaired by the synthetic side-
chain. Receptor binding studies previously conducted for
InsX210 by use of the free fat cell activity (FFC) and mouse
blood glucose assay (MBGA) gave values of 31% (FFC) and 93%
(MBGA). Receptor binding studies have also been performed on
InsX2-bipy[A1] and InsX2-bipy[B29]12 using a human insulin
receptor aﬃnity scintillation proximity assay (HIRAspa).37 For
InsX2-bipy[A1], the receptor binding was found to be 5.2%,
while for InsX2-bipy[B29], it was 29.4%,12 hence still
subnanomolar. Although the diﬀerent methods are not directly
comparable, the results indicate that the receptor binding is not
impaired by adding bipy to the B29 site. Further studies with
other synthetic side chains could potentially lead to faster-acting
insulin analogues applicable in the treatment of diabetes mellitus.
■ CONCLUSION
The nanoscale-scale structures formed by self-assembly of
bipyridine modiﬁed insulin variants have been investigated by
SAXS. The bipymodiﬁcation led to the formation of well-deﬁned
trimers when adding Fe(II). The addition of Zn(II) led to the
formation of the same type of hexamers as those present in
human insulin, however, with a monomer−hexamer equilibrium
signiﬁcantly shifted toward the monomer side. The choice of
binding site position (A1 or B29) for bipy on the insulin
molecule played a signiﬁcant role in the propensity of the system
to form well-ordered trimers and hexamers, respectively. The
choice of bipy binding site also aﬀected the propensity of the
system to form larger and less well-structured molecular
assemblies. Insulin modiﬁed with bipy at position A1 easily
formed both well-ordered oligomers and larger aggregates,
whereas bipy modiﬁcation at position B29 partly suppressed the
formation of well-ordered oligomers and apparently fully
suppressed the formation of larger aggregates. These structural
ﬁndings suggest that the studied insulin analogues display
interesting self-assembly behavior, with potential relevance for
future development of insulin and other biopharmaceutical
drugs. However, detailed pharmaceutical studies would
obviously have to be performed in order to fully elucidate this
potential. An advantage of our strategy for control of protein self-
assembly is the use of non-native ligands. We believe that it can
be extended to other proteins for a wide range of applications in
biopharmaceuticals, chemical biology, and material science.
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